Compare AIRE & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | VNRX |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.7M | 38.2M |
| IPO Year | N/A | N/A |
| Metric | AIRE | VNRX |
|---|---|---|
| Price | $0.44 | $0.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.00 | ★ $3.17 |
| AVG Volume (30 Days) | ★ 3.6M | 2.8M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,149,567.00 | $1,472,007.00 |
| Revenue This Year | $411.48 | $55.33 |
| Revenue Next Year | $141.39 | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 994.18 | 14.48 |
| 52 Week Low | $0.14 | $0.23 |
| 52 Week High | $4.49 | $0.94 |
| Indicator | AIRE | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 36.72 |
| Support Level | $0.51 | $0.23 |
| Resistance Level | $0.53 | $0.31 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 2.60 | 32.56 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.